" class="no-js "lang="en-US"> ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy - Medtech Alert
Friday, April 12, 2024

ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy

ELIAS Animal Health recently presented new mechanism of action data for the ELIAS Cancer Immunotherapy (ECI®) at the 2022 American College of Veterinary Internal Medicine Forum.

ECI is an adoptive cell therapy that stimulates a patient’s immune system to recognize and attack cancers. ECI uses a personalized vaccine made from a patient’s own cancer cells to “prime” the immune cells to recognize the cancer. These primed immune cells—which are collected from the patient through a procedure called apheresis—are activated and expanded ex vivo for reinfusion into the patient, where they travel to the cancer cells and attack them.

In vitro  study demonstrates how vaccine-primed T cells mount an immune response against cancer cells

The mechanism of action for ECI has been demonstrated in an in vitro study using cancer cells and T cells collected from pet dogs being treated with ECI for osteosarcoma, a deadly form of bone cancer. In the presence of target cancer cells, activated T cells from vaccinated dogs demonstrated cytotoxic activity, meaning the T cells acted in such a way to kill cancer cells.

Read: ECI® Mechanism of Action Technical Summary

Results of ECI clinical trial found several long-term cancer survivors

Results from a previously reported clinical trial evaluating ECI in pet dogs with appendicular osteosarcoma were impressive, with several long-term survivors.

A second ECI trial completed enrollment early 2022, with over 100 pet dogs enrolled at 10 sites across the United States. Results from that study are expected late 2022.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more